Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 50.00 67,155 08:00:00
Bid Price Offer Price High Price Low Price Open Price
48.00 52.00 50.00 50.00 50.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.68 -10.87 -6.56 86
Last Trade Time Trade Type Trade Size Trade Price Currency
09:26:51 O 5,000 48.50 GBX

Angle (AGL) Latest News

More Angle News
Angle Takeover Rumours

Angle (AGL) Discussions and Chat

Angle Forums and Chat

Date Time Title Posts
09/4/202009:10ANGLE PLC - 2019 THREAD - LIQUID BIOPSY COMPANY2,475
28/2/201912:22ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET11,356
28/8/201812:29ANGLE plc (AGL) One to Watch -
02/7/201812:06Still time to look at Angle (AGL)-
14/5/201809:44ANGLE (AGL) Strategic Move-

Add a New Thread

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Angle trades in real-time

Angle (AGL) Top Chat Posts

Angle Daily Update: Angle Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 50p.
Angle Plc has a 4 week average price of 43.50p and a 12 week average price of 43.50p.
The 1 year high share price is 85.50p while the 1 year low share price is currently 43.50p.
There are currently 172,754,816 shares in issue and the average daily traded volume is 198,856 shares. The market capitalisation of Angle Plc is £86,377,408.
fraybentos2: even i am a buyer at this share price
andypar: I imagine post FDA approval at some point this year the share price will be approx £1 with a market cap of around £180m. At this point AGL will cease to be a jam tomorrow company and financials / forecasts will actually start to matter. So the key question then becomes how quickly can sales ramp up. To justify the £180m market cap I think we need sales of £30m giving a profit of say £10m. Can they achieve this within 3 years ???? The other more exciting question is how important is our tech to big pharma. Can they risk another player buying us. How much can they increase their profits by, by acquiring us? Optimistic scenario - No more placings, rapid ramp-up in sales from JV's with big players. Get taken over at a large premium over an already high share price - Forecast £2.40 Pessimistic scenario - More placings, JV's slow to get going, 3 years more of losses. Share price 30p and then maybe taken over for 50p. Unfortunately, the history of AIM shows the pessimistic scenario is often more likely. Jam tomorrow often seems to turn into placings today with only directors getting rich. Someone is going to make a lot of money out of parsortix, as the tech is amazing lets hope is AGL shareholders.
sicilian_kan: It is not my outlook that matters but the market's. Look at the share price chart. It tells you everything you need to know about what the market things about the Q-submission news. It doesn't like it for a good reason. Share price down from 77p the day before that news, to 62.3p today, steadily falling throughout that period. I believe that slide will continue and that the chart demonstrates what it thinks of the news. You think that the share price will stabilise because some people bought at this price a few months ago. As an aside, you are assuming the start of January for the meeting.
enteleon: GENOME-WEB UPDATE: Friday, November 15th- Management Board of Qiagen NV (Ticker QGEN on NYSE) confirms that the company is in talks with interested parties regarding takeover. share price climbs 8.8%. Comment: Qiagen has an interesting history. Although domiciled on the Dutch Stock Exchange, its operating HQ is in Hilden, Germany. Regional HQs in Maryland, USA, and Shanghai for Asian operations. Early IPO on Nasdaq Exchange in 1996- the first German Company to do so. In 2018, moved listing to NYSE. 2018 revenue approx $1.5 Billion. Operates more than 35 offices in 25 countries. Genomics England appointed Qiagen to provide bio-informatic support to the NHS Genomic Medical Service and national network of Genomic Laboratory Hubs in efforts to sequence 5 million genomes by 2023. Current market cap: $8.18 Billion; 226.49 Million shares in issue. Share price 3-year low on October 8th, 2019, at $25.42c; current share price $40.56c.
alloa2003: I think the AGL share price is starting to reflect the potential value based on the risk that it may or may not be realised. For example if the potential value was £2 a share (based on profit, pe ratio, etc) and the chance of being successful was deemed 80% then you would expect the price to be much closer to £2. It is a form of arbitration with the share price reflecting the risk/reward factor compared to potential "fair value".
alloa2003: There has been a sea change in the AGL share price of late, no highs then sharp reversals on announcements and no drifting on a lack of news. There is strong underlying demand for the shares which leads me to believe things are afoot behind the scenes.
semper vigilans: As usual a decent bit of research from a large, highly reputable organisation working in the right field, is not really recognised by the market. Whatever one thinks of false starts earlier, at some stage the build up of published, independent research must give the AGL share price a decent, upward shove?
alloa2003: Brexit is not helping sentiment but not the reason for AGL share price weakness. There is literally no interest in the stock at the moment - going to be news driven for some time to come until we see sales and profits. Might drift until it finds support.
alloa2003: I think AGL share price suffers from boredom at times between announcements. Very news driven as profitability is some way off.
alloa2003: Its that time of year - what are your predicitons for the AGL share price in 12 months? I will start at £2 a share :)
Angle share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200409 08:46:23